Not specific to RAC or bisantrene, but as just another retail shareholder..
2 Questions if you don’t mind.
Just in general speaking terms, If i brought a drug off the shelf & started up XYZ biotech Australia. And it turns out theres utility, interest, & clinical need across many continents.
1. Would my smartest commercialisation strategy be targeting a specific indication in a specific country first, to let’s say set the pricing benchmark, before rolling it out to other countries or indications?
2. And let’s say I had 5 possible indications to go after, all each with very different company outcomes: To strike a balance between extracting as much value for my shareholders, where does pricing & size of market of a drug rank when considering a path to commercial outcome?
1. Paths to approval
2. TAM
3. Risk
4. competition
5. patient need
6. Pricing
7. other
General Comments / Chat, page-8673
-
- There are more pages in this discussion • 2,465 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.85 |
Change
0.000(0.00%) |
Mkt cap ! $315.1M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3804 | $1.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.84 | 17 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3804 | 1.840 |
2 | 6500 | 1.830 |
1 | 100 | 1.820 |
7 | 15943 | 1.800 |
1 | 11000 | 1.780 |
Price($) | Vol. | No. |
---|---|---|
1.835 | 17 | 1 |
1.840 | 10000 | 1 |
1.890 | 500 | 1 |
1.940 | 148 | 1 |
1.975 | 2000 | 1 |
Last trade - 08.46am 17/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
Day chart unavailable